Literature DB >> 9642111

Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).

P Stacey1, S Rulten, A Dapling, S C Phillips.   

Abstract

A human PDE5 cDNA has been isolated which contains an open reading frame encoding an 875 amino acid, 100,012 Da polypeptide, the expression of which yields a protein of the predicted size and is capable of hydrolyzing cGMP. The deduced amino acid sequence is very similar (95%) to that of bovine PDE5, and comprises a conserved cGMP-binding domain and catalytic domain. Northern analysis reveals a major and minor transcript of approximately 9 kb and approximately 8 kb respectively, thus indicating the existence of at least two splice variants, the major form being readily detected in bladder, colon, lung, pancreas, placenta, prostate, small intestine, and stomach. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642111     DOI: 10.1006/bbrc.1998.8769

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.

Authors:  Stefan Uckert; Christian G Stief; Margit Mayer; Udo Jonas; Petter Hedlund
Journal:  World J Urol       Date:  2005-12-06       Impact factor: 4.226

2.  Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.

Authors:  Longhu Li; Husnain Kh Haider; Linlin Wang; Gang Lu; Muhammad Ashraf
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

3.  A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors.

Authors:  Nermin S Ahmed; Bernard D Gary; Gary A Piazza; Heather N Tinsley; Stefan Laufer; Ashraf H Abadi
Journal:  Med Chem       Date:  2010-11       Impact factor: 2.745

4.  Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil.

Authors:  Chandrashekhar S Patil; Vijay Pal Singh; Shrinivas K Kulkarni
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

5.  Phosphodiesterase type 5 and high altitude pulmonary hypertension.

Authors:  A A Aldashev; B K Kojonazarov; T A Amatov; T M Sooronbaev; M M Mirrakhimov; N W Morrell; J Wharton; M R Wilkins
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

6.  Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.

Authors:  Alberto J Kaumann; Alejandro Galindo-Tovar; Elisa Escudero; María Luisa Vargas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-20       Impact factor: 3.000

7.  Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.

Authors:  M Bertolotto; E Trincia; R Zappetti; R Bernich; G Savoca; M A Cova
Journal:  Radiol Med       Date:  2009-08-20       Impact factor: 3.469

8.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 9.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

Review 10.  Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Authors:  Ibrahim A Abdel-Hamid
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.